Products Categories
CAS No.: | 7773-01-5 |
---|---|
Name: | Manganese chloride |
Article Data: | 161 |
Molecular Structure: | |
Formula: | MnCl2 |
Molecular Weight: | 125.844 |
Synonyms: | Manganese chloride;CCRIS 6882;HSDB 2154;Manganese bichloride;Manganese dichloride;Manganous chloride;NSC 9879;Scacchite;UNII-6YB4901Y90; |
EINECS: | 231-869-6 |
Density: | 2.98 g/cm3 |
Melting Point: | 652 °C(lit.) |
Boiling Point: | 1225 °C |
Flash Point: | 1190°C |
Solubility: | 723 g/L (25 °C) in water |
Appearance: | Rose red crystalline powder |
Hazard Symbols: | Xn |
Risk Codes: | 22-52-48/22-25 |
Safety: | 45-61-22-36 |
Transport Information: | UN 3288 6.1/PG 3 |
PSA: | 0.00000 |
LogP: | -5.99200 |
Manganous chloride anhydrous is also called as Manganese dichloride with the chemical formula MnCl2. The substance has the CAS register number 7773-01-5 and the EINECS number 231-869-6. It is soluble in water but moisture sensitive, which is hygroscopic. In addition, Manganous chloride anhydrous is incompatible with strong acids, reactive metals, hydrogen peroxide. This chemical is rose red crystalline powder. Manganism, or manganese poisoning, can be caused by long-term exposure to manganese dust or fumes.
Properties: Manganous chloride anhydrous is a polymeric solid, which adopts a layered cadmium chloride-like structure. Upon treatment with typical organic ligands, manganese(II) undergoes oxidation by air to give Mn(III) complexes. Examples include [Mn(EDTA)]-, [Mn(CN)6]3-, and [Mn(acetylacetonate)3]. Triphenylphosphine forms a labile 2:1 adduct:
MnCl2 + 2 Ph3P → [MnCl2(Ph3P)2]
Manganous chloride anhydrous is a weak Lewis acid, reacting with chloride ions to produce a series of solids containing the following ions [MnCl3]-, [MnCl4]2-, and [MnCl6]4-. Both [MnCl3]- and [MnCl4]2- are polymeric. Manganous chloride anhydrous serves as a starting point for the synthesis of a variety of manganese compounds. For example, manganocene is prepared by reaction of MnCl2 with a solution of sodium cyclopentadienide in THF.
MnCl2 + 2 NaC5H5 → Mn(C5H5)2 + 2 NaCl
Preparation: Manganous chloride anhydrous can be prepared by manganese metal or manganese(II) carbonate and hydrochloric acid in the laboratory:
Mn + 2 HCl → MnCl2 + H2
MnCO3 + 2 HCl → MnCl2 + H2O + CO2
Moreover, it can also be produced by pyrolusite restored by pulverized coal to give manganous oxide or directly by manganese ore, and then reacts with concentrated hydrochloric acid. After that, via filtration, impurity removing, concentration, crystallization and centrifugal separation, you can get the end product of Manganous chloride.
MnO2 + C → MnO + CO
MnO2 + CO → MnO + CO2↑
MnO + 2 HCl → MnCl2 + H2O
MnO2 + 2 HCl → MnCl2 + 2 H2O + Cl2↑
Uses: Manganous chloride is the precursor to the antiknock compound methylcyclopentadienyl manganese tricarbonyl. The main application is used in the production of dry cell batteries. Manganous chloride anhydrous is also used in 31P-NMR to determine the size and lamellarity of phospholipid vesicles. Manganous chloride can be used as conductive salt in electroplating. Meanwhile, it is used as antioxidants which can restrain the oxidation of ferrous.
When you are using Manganous chloride anhydrous, please be cautious about it. It is harmful and toxic if swallowed. In addition, it is harmful to aquatic organisms. There will be a danger of serious damage to health by prolonged exposure if swallowed. When using it, you should wear suitable protective clothing. In case of accident or if you feel unwell, you can seek medical advice immediately. Finally, you must avoid release to the environment.
You can still convert the following datas into molecular structure of Manganous chloride anhydrous:
(1)Canonical SMILES: Cl[Mn]Cl
(2)InChI: InChI=1S/2ClH.Mn/h2*1H;/q;;+2/p-2
(3)InChIKey: GLFNIEUTAYBVOC-UHFFFAOYSA-L
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
cat | LDLo | unreported | 4mg/kg (4mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. | |
dog | LD50 | intravenous | 202mg/kg (202mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
dog | LDLo | parenteral | 128mg/kg (128mg/kg) | CARDIAC: OTHER CHANGES VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION GASTROINTESTINAL: OTHER CHANGES | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. |
dog | LDLo | unreported | 600ug/kg (0.6mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. | |
guinea pig | LD50 | oral | 916mg/kg (916mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 36(9), Pg. 15, 1971. |
guinea pig | LDLo | subcutaneous | 180mg/kg (180mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
guinea pig | LDLo | unreported | 60mg/kg (60mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. | |
mouse | LD50 | intramuscular | 255mg/kg (255mg/kg) | Russian Pharmacology and Toxicology Vol. 38, Pg. 221, 1975. | |
mouse | LD50 | intraperitoneal | 121mg/kg (121mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 244, Pg. 17, 1962. | |
mouse | LD50 | intravenous | 38mg/kg (38mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: ATAXIA | Acta Radiologica. Vol. 38, Pg. 770, 1997. |
mouse | LD50 | oral | 1031mg/kg (1031mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 36(9), Pg. 15, 1971. |
mouse | LDLo | subcutaneous | 210mg/kg (210mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rabbit | LDLo | intravenous | 64800ug/kg (64.8mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rabbit | LDLo | parenteral | 41mg/kg (41mg/kg) | CARDIAC: OTHER CHANGES GASTROINTESTINAL: OTHER CHANGES VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. |
rabbit | LDLo | subcutaneous | 180mg/kg (180mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rabbit | LDLo | unreported | 6500ug/kg (6.5mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 102, Pg. 262, 1929. | |
rat | LD50 | intramuscular | 700mg/kg (700mg/kg) | Russian Pharmacology and Toxicology Vol. 38, Pg. 221, 1975. | |
rat | LD50 | intraperitoneal | 147mg/kg (147mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Indian Journal of Pharmacology. Vol. 23, Pg. 153, 1991. |
rat | LD50 | intravenous | 92600ug/kg (92.6mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Indian Journal of Pharmacology. Vol. 23, Pg. 153, 1991. |
rat | LD50 | oral | 250mg/kg (250mg/kg) | Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 26(12), Pg. 8, 1961. |